Prognostic significance of estrogen receptor expression in ovarian cancer: Immunoreactive Score (IRS) vs. Composition Adjusted Receptor Level (CARL)

D. G. Kieback; M. F. Press; E. N. Atkinson; G. L. Edwards; V. J. Mobus; I. B. Runnebaum; R. Kreienberg; L. A. Jones

Prognostic significance of estrogen receptor expression in ovarian cancer: Immunoreactive Score (IRS) vs. Composition Adjusted Receptor Level (CARL)

D. G. Kieback, M. F. Press, E. N. Atkinson, G. L. Edwards, V. J. Mobus, I. B. Runnebaum, R. Kreienberg, L. A. Jones

Health Disparities Research

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Abstract

An Immunoreactive Score (IRS) was compared to the Composition Adjusted Receptor Level (CARL) evaluating prognostic significance of estrogen receptor (ER) expression in 61 ovarian cancers after ≥ 8 years. CARL of ER allowed for calculating individual risk curves in stage III and IV, Grade 2 and 3, serous ovarian carcinoma after surgical debulking to ≤ 2 cm residual and platinum based chemotherapy. In overall analysis and in subsets defined by tumor stage, grade or a combination thereof significant prognostic distinction became possible using a cutoff IRS of 4 vs. 0 or vs. scores ≤ 3. This study substantiates ER as a prognostic variable in human ovarian cancer and for the first time establishes the value of an IRS.

Original language	English (US)
Pages (from-to)	2489-2496
Number of pages	8
Journal	Anticancer research
Volume	13
Issue number	6 B
State	Published - 1993

Keywords

CARL immunohistochemistry
Estrogen receptor
Human ovarian cancer
Immunoreactive score
Prognosis

ASJC Scopus subject areas

Oncology
Cancer Research

Cite this

@article{d4ed4573979645eeb723f264cbfd44cb,

title = "Prognostic significance of estrogen receptor expression in ovarian cancer: Immunoreactive Score (IRS) vs. Composition Adjusted Receptor Level (CARL)",

abstract = "An Immunoreactive Score (IRS) was compared to the Composition Adjusted Receptor Level (CARL) evaluating prognostic significance of estrogen receptor (ER) expression in 61 ovarian cancers after ≥ 8 years. CARL of ER allowed for calculating individual risk curves in stage III and IV, Grade 2 and 3, serous ovarian carcinoma after surgical debulking to ≤ 2 cm residual and platinum based chemotherapy. In overall analysis and in subsets defined by tumor stage, grade or a combination thereof significant prognostic distinction became possible using a cutoff IRS of 4 vs. 0 or vs. scores ≤ 3. This study substantiates ER as a prognostic variable in human ovarian cancer and for the first time establishes the value of an IRS.",

keywords = "CARL immunohistochemistry, Estrogen receptor, Human ovarian cancer, Immunoreactive score, Prognosis",

author = "Kieback, {D. G.} and Press, {M. F.} and Atkinson, {E. N.} and Edwards, {G. L.} and Mobus, {V. J.} and Runnebaum, {I. B.} and R. Kreienberg and Jones, {L. A.}",

year = "1993",

language = "English (US)",

volume = "13",

pages = "2489--2496",

journal = "Anticancer research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "6 B",

}

TY - JOUR

T1 - Prognostic significance of estrogen receptor expression in ovarian cancer

T2 - Immunoreactive Score (IRS) vs. Composition Adjusted Receptor Level (CARL)

AU - Kieback, D. G.

AU - Press, M. F.

AU - Atkinson, E. N.

AU - Edwards, G. L.

AU - Mobus, V. J.

AU - Runnebaum, I. B.

AU - Kreienberg, R.

AU - Jones, L. A.

PY - 1993

Y1 - 1993

N2 - An Immunoreactive Score (IRS) was compared to the Composition Adjusted Receptor Level (CARL) evaluating prognostic significance of estrogen receptor (ER) expression in 61 ovarian cancers after ≥ 8 years. CARL of ER allowed for calculating individual risk curves in stage III and IV, Grade 2 and 3, serous ovarian carcinoma after surgical debulking to ≤ 2 cm residual and platinum based chemotherapy. In overall analysis and in subsets defined by tumor stage, grade or a combination thereof significant prognostic distinction became possible using a cutoff IRS of 4 vs. 0 or vs. scores ≤ 3. This study substantiates ER as a prognostic variable in human ovarian cancer and for the first time establishes the value of an IRS.

AB - An Immunoreactive Score (IRS) was compared to the Composition Adjusted Receptor Level (CARL) evaluating prognostic significance of estrogen receptor (ER) expression in 61 ovarian cancers after ≥ 8 years. CARL of ER allowed for calculating individual risk curves in stage III and IV, Grade 2 and 3, serous ovarian carcinoma after surgical debulking to ≤ 2 cm residual and platinum based chemotherapy. In overall analysis and in subsets defined by tumor stage, grade or a combination thereof significant prognostic distinction became possible using a cutoff IRS of 4 vs. 0 or vs. scores ≤ 3. This study substantiates ER as a prognostic variable in human ovarian cancer and for the first time establishes the value of an IRS.

KW - CARL immunohistochemistry

KW - Estrogen receptor

KW - Human ovarian cancer

KW - Immunoreactive score

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=0027815665&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027815665&partnerID=8YFLogxK

M3 - Article

C2 - 8135488

AN - SCOPUS:0027815665

SN - 0250-7005

VL - 13

SP - 2489

EP - 2496

JO - Anticancer research

JF - Anticancer research

IS - 6 B

ER -

Prognostic significance of estrogen receptor expression in ovarian cancer: Immunoreactive Score (IRS) vs. Composition Adjusted Receptor Level (CARL)

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this